Apomorphine is a direct stimulant of dopamine receptors and while possessing both D1 and D2 receptor agonist properties does not share transport or metabolic pathways with levodopa. Its actions on parkinsonian motor disability are likely to be mediated at post-synaptic receptor sites.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Apomorphine is the active ingredient of these drugs:
Austria Cyprus Estonia Finland Ireland
Austria Estonia Finland Ireland Lithuania
Canada United States
Australia Canada New Zealand
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):